Johnson & Johnson stock holds above $268 as FY 2026 outlook stays intact
Published on 08/30/2026 at 16:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson Inc. (US4781601046) stock is trading around $268 per share in late August 2026, with investors weighing the company’s FY 2026 earnings outlook against a steady valuation backdrop as of August 29, 2026.
Recent market data for Johnson & Johnson shows the shares at $268.04 on the Cboe venue, reflecting a daily gain of 0.87 percent and a year-to-date advance of 28.38 percent as of August 29, 2026, signaling resilient performance within large-cap healthcare.
On the fundamentals side, Johnson & Johnson has confirmed FY 2026 guidance for earnings per share in a range from $11.60 to $11.75, and equity analysts collectively project EPS of $11.61 for the current year, underlining management’s confidence in cash generation and margin stability.
Guidance and analyst consensus
According to a detailed analyst overview of Johnson & Johnson published on August 30, 2026, the company has set its full-year 2026 guidance at $11.60 to $11.75 in EPS, framing investor expectations for earnings growth over the current fiscal period and providing a reference point for valuation at the latest share price. This same overview highlights that analysts as a group anticipate Johnson & Johnson will deliver $11.61 in EPS for fiscal 2026, effectively aligning consensus with the lower end of the management-guided range.
The rating distribution summarized in the same analyst coverage shows one Strong Buy recommendation, eighteen Buy ratings, and six Hold ratings on the stock, which adds up to an average rating characterized as Moderate Buy, indicating that the majority of covering analysts expect positive total returns over a 12-month horizon from the current valuation level.
Price-target data compiled in recent market commentary points to a mean target of $276.29 for Johnson & Johnson shares, implying upside potential of 3.1 percent from the latest price area near $268, a modest but positive gap that suggests analysts view the stock as slightly undervalued relative to their expectations for FY 2026 earnings delivery.
Share performance and valuation signals
Market-level performance metrics underscore Johnson & Johnson’s role as a steady compounder in the healthcare space, with the stock’s year-to-date gain of 28.38 percent as of August 29, 2026 outpacing many defensive peers and reflecting investor confidence in the company’s diversified portfolio of pharmaceuticals, medical devices, and consumer health products.
The relationship between the current share price around $268 and the FY 2026 EPS guidance range of $11.60 to $11.75 equates to a prospective price-to-earnings multiple in the mid-20s, a level that positions Johnson & Johnson at a premium to some traditional consumer-staples names but in line with quality large-cap healthcare groups that combine durable cash flows with innovation-driven growth.
Forward-looking models published on August 30, 2026 highlight that Johnson & Johnson’s projected share-price path for August 2026 centers on an average forecast just above $272, with a monthly maximum scenario above $275 and a percentage change of 2.66 percent for the period, illustrating a consensus view of incremental gains rather than dramatic re-rating over the very short term.
Dividend profile and income appeal
Dividend metrics remain a central pillar of the Johnson & Johnson equity story, with the company’s current quarterly payout at $1.34 per share, pointing to an annualized dividend of $5.36 and representing a yield of 2.0 percent when measured against the late-August 2026 share price area of roughly $268.
Based on the same analyst data, Johnson & Johnson’s dividend payout ratio currently stands at 62.11 percent of earnings, a level that balances robust cash returns to shareholders with retained earnings available for investment in research and development, bolt-on acquisitions, and potential balance-sheet strengthening.
For income-oriented investors, the combination of a 2.0 percent yield, a long-established track record of regular dividends, and the guided FY 2026 EPS range suggests that the company has ample room to sustain and potentially grow its payout over time, provided that operational execution remains consistent with current consensus expectations.
Operational breadth and product engine
Beyond financial metrics, Johnson & Johnson continues to engage in research, development, manufacturing, and sales across a broad spectrum of healthcare products worldwide, spanning innovative pharmaceuticals, medical technology solutions, and consumer health offerings designed to support everyday wellness.
Recent commentary on the company’s pipeline describes ongoing work on first-in-class therapies targeted at complex and rare conditions, reinforcing Johnson & Johnson’s strategic emphasis on high-value, differentiated treatments where clinical innovation can translate into durable revenue streams and competitive moats.
The breadth of the portfolio, from advanced oncology drugs and immunology treatments to surgical devices and over-the-counter health staples, provides multiple levers for growth, smoothing out the impact of lifecycle transitions at individual products and supporting the earnings guidance that management has set for FY 2026.
Representative product: anemia treatment focus
One representative example of Johnson & Johnson’s innovation agenda is its activity around therapies for rare anemia indications, where the company is working on first-in-class treatment approaches intended to address underlying disease mechanisms and improve patient outcomes in areas historically underserved by existing options.
In this segment, Johnson & Johnson’s development strategy integrates advanced clinical research, close collaboration with medical practitioners, and a focus on real-world evidence to refine dosing, safety, and efficacy profiles, aiming to bring new standards of care to patients living with chronic and complex hematologic conditions.
The anemia-treatment effort also illustrates how Johnson & Johnson’s product engine ties directly into its financial outlook, as successful launches of high-value specialty medicines can contribute meaningfully to the revenue base over the FY 2026 period and beyond while reinforcing the company’s reputation as a leader in cutting-edge healthcare solutions.
Closing stock snapshot
As of the Cboe close on August 29, 2026, Johnson & Johnson stock trades at $268.04 per share in USD, with a daily gain of 0.87 percent and a year-to-date performance of 28.38 percent, placing the shares modestly below the mean analyst price target of $276.29 and leaving scope for further appreciation if FY 2026 earnings and cash flows track the guided range.
Fact box
Company: Johnson & Johnson Inc.
ISIN: US4781601046
Ticker: JNJ
Exchange: Cboe / NYSE listing context
Price (as of August 29, 2026, 4:00 p.m. ET): $268.04 USD
Market cap: large-cap healthcare (value consistent with $268.04 share price as of August 29, 2026)
Sector / Industry: Healthcare - Pharmaceuticals, medical devices, consumer health
Index membership: S&P 500
